A novel technique for microaxial left ventricular assist device insertion via transcervical transcarotid approach

Armaan Akbar, BS, Bryon Tompkins, MD, Ahmet Kilic, MD

PII: S2666-2507(23)00387-5
DOI: https://doi.org/10.1016/j.xjtc.2023.10.007
Reference: XJTC 1536

To appear in: JTCVS Techniques

Received Date: 4 August 2023
Revised Date: 30 September 2023
Accepted Date: 9 October 2023

Please cite this article as: Akbar A, Tompkins B, Kilic A, A novel technique for microaxial left ventricular assist device insertion via transcervical transcarotid approach, JTCVS Techniques (2023), doi: https://doi.org/10.1016/j.xjtc.2023.10.007.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2023 The Authors. Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery
A novel technique for microaxial left ventricular assist device insertion via transcervical transcarotid approach

Armaan Akbar, BS¹, Bryon Tompkins, MD¹ and Ahmet Kilic, MD¹

¹ The Johns Hopkins Hospital, Division of Cardiac Surgery, Department of Surgery, Baltimore, MD. 21287

Word Count: 749

Disclosures: The authors report no conflicts of interest.

Funding: None

Corresponding Author:
Ahmet Kilic, MD
The Johns Hopkins Hospital
Division of Cardiac Surgery
1800 Orleans Street, Zayed 7107
Baltimore, MD 21287
Glossary of abbreviations: AVR, aortic valve replacement; IABP, intra-aortic balloon pump; LA, Left atrium; LV, left ventricle; MCS, mechanical circulatory support; PA, pulmonary artery; RV, right ventricle.

Central image

Caption: Transthoracic echocardiogram showing Impella 5.5 placement in left ventricle.

Central message: Transcervical transcarotid Impella 5.5 insertion is a viable option for full circulatory support and left ventricular offloading to provide periprocedural support in high-risk cases.
Introduction

The Impella 5.5’s (Abiomed, Danvers, MA) ability to offload the left ventricle (LV) and potential for flexibility in implantation demonstrate its remarkable utility as periprocedural support for high-risk surgical cases. Herein we describe a novel transcervical transcarotid Impella insertion, avoiding central cannulation in a situation where the axillary artery could not be used. IRB approval was not required for this study; the need for informed written consent was also waived.

Case

A 61-year-old male with long standing heart failure was admitted with acute-on-chronic exacerbation of his valvular cardiomyopathy. He had severe aortic insufficiency with a reduced ejection fraction in 2016 for which he underwent an aortic valve replacement (AVR) with a 27-mm Trifecta pericardial tissue valve (Abbott, St Paul, MN, USA).

Right heart catheterization revealed a cardiac index of 1.7 L/min/m², 29 mmHg pulmonary capillary wedge pressure, and 42 mmHg mean pulmonary artery (PA) pressure. Due to his small stature (1.63 m, 74 kg) and axillary artery diameter of 5 mm, he underwent an axillary intra-aortic balloon pump (IABP) placement as bridge to transplantation. Subsequently elevated PA pressures and unfavorable blood type O led to the decision to increase his support to Impella 5.5 as a bridge to decision contingent on his PA pressures.

Given hostile sternal anatomy on computed tomography (CT), recent pneumonia, small axillary diameter, and favorable carotid artery diameter of 6.5 mm, we proceeded with a transcervical
transcarotid Impella insertion utilizing transesophageal echocardiogram and fluoroscopy through the existing tissue AVR.

In the operating room, the IABP was removed from its axillary position. A neck incision was made 1 cm above the sternal notch on the anterior sternocleidomastoid (Figure 1). Heparin was administered to achieve an activated clotting time (ACT) >250. Lacking a preoperative head and neck CT due to the patient’s acute-on-chronic renal insufficiency, a test occlusion of the carotid was performed utilizing vessel loops proximal and distal to the common carotid artery with bilateral cerebral near infrared spectroscopy oximeters. Oximetry revealed no measurable drop in cerebral saturation, and saturation remained near baseline for the remainder of the case. A 10-mm graft was tunneled laterally in the supraclavicular region and vessel loops tightened for proximal and distal control with subsequent end to side anastomosis of the graft to the right carotid with a 5-0 prolene suture. The patient was placed in steep Trendelenburg position and the graft de-aired by loosening the proximal vessel loop while maintaining tension on the distal vessel loop. A vascular clamp was applied to the graft, the Impella sheath was introduced and secured utilizing the manufacturer’s clips, and the side port of the sheath was de-aired in usual surgical fashion. The Impella device was then placed utilizing techniques previously discussed with Glidewire (Terumo, Tokyo, Japan) as the initial method to cross the tissue AVR and obtain access into the LV cavity. An angled pigtail (Cordis, Miami Lakes, FL) was utilized to exchange to a stiff wire (Abbott Vascular, Santa Clara, CA) and the Impella device was introduced into the LV (Figure 2).
Impella was started at a minimal flow of P2 and uptitrated to a flow between 2.5–3.5 liter/min, and the patient was extubated in the operating room with fully intact neurological examination.

His recovery consisted of continued elevation of his PA pressures despite optimal off-loading of the LV, inotrope support for the right ventricle, and diuresis. As a result, he was implanted with a durable left-ventricular assist device on day 8 of support.

**Discussion**

Temporary mechanical circulatory support (MCS) has gained popularity in its versatility as a bridge to recovery, bridge to definitive therapy, or bridge to life-ending decision making. The Impella 5.5 is a surgically placed temporary MCS that requires an 8-10 mm graft designed for approach from upper extremity vessels. Over 12,000 have been implanted since introduction to the market in 2019. The Impella 5.5 has gained popularity to its utility in directly offloading the LV, remote monitoring capabilities, ability to provide real time hemodynamics of the LV end diastolic pressure, and relative freedom from hemolysis.

Although the Impella 5.5’s main use has been in heart failure and cardiogenic shock, it has gained momentum as periprocedural support in high-risk surgical cases. We describe a novel implantation technique in a situation requiring hemodynamic support without the need for an invasive central strategy. This approach has been described with Impella 5.0 as a temporizing measure for patients in cardiogenic shock.
Careful cerebral oximetry monitoring allowed us to successfully use this technique for temporary periprocedural support. This technique is a viable last resort maneuver in the armamentarium of surgeons who treat heart failure with the need for temporary support. Further discussion is provided in Appendix 1.

References


Figure 1. The right cervical incision at the medial border of the sternocleidomastoid is shown both postoperatively and intra-operatively (*) with anastomosis to right carotid artery. The graft tunnel exit site in the supraclavicular region (+) as well as previous sternotomy for aortic valve replacement (^) are additionally present.
Figure 2. Chest radiograph (A) and transthoracic echocardiography image (B) from post-operative day 1 showing Impella 5.5 placement in left ventricle. LA, left atrium; LV, left ventricle; RV, right ventricle.
Appendix 1

Anatomic considerations

Our patient’s axillary artery diameter of 5 mm was below our minimum recommendation of 7 mm and was deemed inadequate for Impella 5.5 implantation. His common carotid artery diameter of 6.5 mm was adequate; we recommend a minimum carotid artery diameter of 6 mm for safe transcarotid Impella 5.5 implantation without compromising blood flow to the brain.

Anticoagulation strategy

Heparin was administered to achieve an activated clotting time (ACT) > 250 during wire and device manipulation and placement. Subsequently, systemic heparin was utilized, and heparin was additionally used as a purge system for the Impella 5.5. To prevent embolization during explantation, proximal and distal control of the carotid artery was obtained using vessel loops. The distal end was lifted as the device was removed. After explantation, the proximal end was subsequently lifted to allow the vessel to backbleed and flush debris as the distal vessel loop was gently released.